Nottingham, United Kingdom

Marc Geoffery Hummersone

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Marc Geoffery Hummersone: Innovator in Therapeutic Compounds

Introduction

Marc Geoffery Hummersone is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of therapeutic compounds, holding two patents that focus on innovative solutions for treating proliferative disorders such as cancer.

Latest Patents

Hummersone's latest patents include the development of 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds. This invention pertains to pharmaceutical compositions that utilize these compounds to inhibit cell proliferation. The compounds are designed for both in vitro and in vivo applications, specifically targeting proliferative disorders like cancer. His second patent involves 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amides. Similar to his first patent, this invention also focuses on therapeutic applications and methods for preparing these compounds.

Career Highlights

Marc Hummersone is currently associated with Pharminox Limited, where he continues to innovate in the field of therapeutic compounds. His work is characterized by a commitment to developing effective treatments for serious health conditions.

Collaborations

Hummersone collaborates with notable colleagues, including Malcolm Francis Graham Stevens and David Cousin. Their combined expertise contributes to the advancement of therapeutic innovations.

Conclusion

Marc Geoffery Hummersone is a distinguished inventor whose work in therapeutic compounds has the potential to significantly impact the treatment of cancer and other proliferative disorders. His contributions to the field are noteworthy and reflect a dedication to improving health outcomes through innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…